Skip to Navigation
Skip to Main Content
Skip to Related Content
to view your mail
Yahoo Finance Plus
U.S. markets open in 3 hours 23 minutes
Russell 2000 Futures
CRISPR Therapeutics AG (CRSP)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
8,889 reactions on $CRSP conversation
Sign in to post a message.
CRISPR is looking great this morning! Price & volume are moving! If we close above $100
today, this will continue in an upward trend. As we speak, we just past $102.50!!
Hold onto your shares!! There are rumors out there!!!
CRISPR Therapeutics: All about the price tag
CRISPR Therapeutics probably would have been bought out a while back if its share price hadn't gone parabolic earlier this year. CRISPR is working with biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX) on a therapy called CTX001 for the treatment of transfusion-dependent beta thalassemia and sickle cell disease. Vertex also holds an equity stake in the gene-editing company. If CTX001 bears fruit in the clinical, this single rare-disease therapy could easily post blockbuster sales figures.
But that's not what's impressive about CRISPR. The company also has clinical candidates for various forms of cancer, regenerative medicine, and a host of rare diseases such as the muscle-wasting disorder Duchenne muscular dystrophy. Now, the company did post underwhelming initial results for its first blood cancer candidate blood cancer candidate CTX110 earlier this week. But CRISPR's management believes that additional doses of the therapy should improve its durability, and hence its appeal as a truly needle-moving therapy for large B-cell lymphoma. A pivotal trial for this therapy could get under way as soon as next year.
Who is the potential suitor? Like Adaptimmune, CRISPR is likely to have multiple companies knocking at its door in 2022. Vertex is the obvious choice, via its rare blood disease collaboration. But Gilead Sciences (NASDAQ:GILD) has shown a keen interest in oncology over the past half-decade, and it has the cash to pull off the deal. Moderna (NASDAQ:MRNA) could also be in play. Moderna has a penchant for cutting-edge technology, it's flush with cash, and it desperately needs another revenue stream outside its COVID-19 vaccine to justify its valuation.
What's the big picture? A deal for CRISPR probably all comes down to the price tag. Even though the company's market cap is under $8 billion, management may want a figure in the $20 billion to perhaps $30 billion range. CRISPR is a novel drug development platform that can be applied in myriad ways to a variety of genetically based diseases. As such, it would be financially irresponsible to sell the biotech for anything less than a monstrous premium. In fact, this possible buyout may be the largest deal in the entire industry next year.
I thought the positive response number (38% approx.) was an excellent result. However, it's a bit of a downer that the Raymond James analyst said the drug may only be used in very late stages as a you-got-nothing-to-lose last resort. Still, anyone afflicted with this disease, for which there is no known cure at present, will gladly take anything that offers an almost 4 in 10 chance of remission and/or improvement.
Will Finish the day right at 103
I thought the purpose of this board is to share helpful information to other investors. I don't understand why people are talking down on the company that they don't want. Incorrect or bias comment really hurt investor instead helping. Why they are even on this board?
Amazing Ark bought just under 700k shares between 2 funds today. They have spent around 130 million on Crsp in the last week. Don’t know what they are thinking. Stifel only has a 101 target.
I was diagnosed with what the doctor referred to as a low grade lymphoma that is also present in my bone marrow. In a nutshell, I am not producing enough red blood cells. Initially I was put on a regimen of Vitamin B-12 and Folic Acid. So far, so good. Things haven't improved, but they haven't gotten worse. There's no known cure for what I and others have, but any drug that would offer me even a 10% chance to beat this, well, sign me up. CRISPR's results are at least three times better than that. JMHO, because I'm not a doctor nor a scientist, I don't believe there is going to ever be a drug that will annihilate cancer completely. Those afflicted would be foolish to wait for that ultimate elixir. I hope this drug gets approved. It showed a great result for, what was it, 9 of the 24 patients? That's roughly 38%. Since, when I was diagnosed, I was told there is no known cure, I would sign up for that result in a heartbeat because I just might be one of the luckier ones.
its ok, revolutionary medicine takes time and I can wait.
Data was very solid! Showed the treatment was safe and has enough efficacy in the consolidated doses to expand the trial in 2022.
Remember this first phase is to mainly prove safety more so than efficacy. They are working on patients with the most aggressive cancer and giving lower dosages.
This is a great step in the right direction. Other drugs with the same safety profile and efficacy have been approved already.
Based on data today, the odds of full FDA approval rise a decent bit. Wait until the presentation to hear more
CTX110: 58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis
Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion
Response rates and durability are similar to approved autologous CD19 CAR-T therapies on an ITT basis
Positively differentiated safety profile; no Grade 3 or higher cytokine release syndrome (CRS) and low rates of infection and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Expanding CARBON into a potentially registrational trial in 1Q 2022
Management to host webcast and conference call today at 4:30 PM ET
CRSP!!! See the pattern!?!
$160 - Outperform - JMP - 10/14
$171 - Buy - Roth - 10/13
$220 - Buy - Truist - 10/13
$176 - Buy Jefferies - 10/13
$170 - Buy Needham - 10/13
$125 - outperform - Evercore -10/13
$185 - Outperform - Oppenheimer - 10/13
A bunch more but not writing it all out for 10/13 - 145, 160, 171, 117,180,155
CRISPR took a dump today. It reported the results of phase 1 trial results for its blood cancer candidate CTX110. After 6 months, the cancer free result patients are less than other two CAR-T therapies from Novartis and Gilead. However, CRISPR does not have adverse effect that could have serious and potentially life-threatening safety issues. I view this as a major positive and important benefit. Chemotherapy at present is probably the most effective treatment for cancer. However, chemotherapy kills healthy cells along with the cancer cells. This weakens the body of the patients which not only makes life miserable but success is also not guaranteed. As long as the CTX100 has no dangerous effect, the dosage could be increased or an additional treatment could be added. This is a phase 1 trail; correct dosage is yet to be determined. This is normal for most drug tests. Launching phase 2 should not include changing the treatment. Patients that did not respond could receive a 2nd dose/booster. New trail patients would receive increase dosage.
I invested in CRISPR as I like the story. I love to see cures for incurable health issues. I hope CRISPR to be successful not only for personal gains but I sincerely hope that it could save lives. Good Luck to all the Longs.
Woods bough this in mid $100s, where is she now on a big discount?
Data is amazing complete response rate 38%, for one of the most aggressive cancers when all other treatments have failed. Thats an unbelievable result.
I applaud the addition of the new CFO. I was a beneficiary of his expertise
with the Translate Bio buy out buy Sanofi. He was involved in building Translate's
growth. This is a good move for moving forward and growing into an established
company. Good move.
We closed above 100, which is very positive! Tomorrow, I anticipate seeing CRSP, easily in the range of $105-110. Any movement upward is great!!! We are still very undervalued!!
CRSP has been the subject of a number of research analyst reports. Canaccord Genuity increased their target price on CRISPR Therapeutics from $151.00 to $160.00 and gave the company a “buy” rating in a report on Monday, August 16th. raised shares of CRISPR Therapeutics from a “sell” rating to a “neutral” rating and upped their price target for the stock from $55.00 to $132.00 in a research note on Monday, June 14th. Citigroup raised shares of CRISPR Therapeutics from a “sell” rating to a “neutral” rating and upped their price target for the stock from $55.00 to $132.00 in a research note on Monday, June 14th. Chardan Capital dropped their price target on shares of CRISPR Therapeutics from $175.00 to $171.00 and set a “buy” rating on the stock in a research note on Friday, July 30th. Finally, TheStreet raised shares of CRISPR Therapeutics from a “d” rating to a “c+” rating in a research note on Monday, August 9th. Two analysts have rated the stock with a sell rating, five have given a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $162.94.
Why the takeover chatter ? Any information is welcome
These medical tickers have waves of movement, 98 will feel like a good price when that wave comes, of course we don’t know when that is but it’ll happen
A broker downgraded CRSP to 95 last week, after a decline 95 from 165. What next, an upgrade to $200 after a retrace to $160?
Salmonella outbreak linked to onions: Throw away onions if you don't know where they're from, CDC says
The world’s most expensive avocado toast is made of solid gold
Yahoo Finance Video
Bitcoin's all-time high rise reignites $100,000 speculation
Yahoo Finance UK
Advertise with us
© 2021 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research